Literature DB >> 2929466

Cardiac arrhythmias and heart rate in hyperthyroidism.

K von Olshausen1, S Bischoff, G Kahaly, S Mohr-Kahaly, R Erbel, J Beyer, J Meyer.   

Abstract

The arrhythmia profile and heart rate (HR) were analyzed by 24-hour Holter monitoring in 37 hyperthyroid patients before (triiodothyronine [T3] hormone level = 331 +/- 108 ng/dl), during (T3 level = 202 +/- 98 ng/dl) and after an antihyperthyroid therapy of 8 to 89 weeks' duration (T3 level = 149 +/- 41 ng/dl). The data were compared with those of 50 control subjects free from cardiac disease. Only 12 hyperthyroid patients (32%) had complex ventricular arrhythmias (Lown grade 3 or 4) as compared with 6 normal subjects (12%, p greater than 0.05). Three patients (8%) had repetitive ventricular arrhythmias (Lown grade 4A/B) as compared with 4 normal subjects (8%, p greater than 0.05). Supraventricular premature complexes occurred more often in hyperthyroid patients than in normal subjects before and after therapy (p less than 0.001). The prevalence of supraventricular tachycardia decreased from 8 patients to 1 during therapy (p less than 0.002). The HR decreased from 95 +/- 13 to 79 +/- 9 beats/min after therapy, but was still increased as compared with the normal subjects (72 +/- 8 beats/min, p less than 0.001). A day/night difference in HR greater than 10% was found in 32 patients (86%) and was more pronounced than in the normal group (p less than 0.001). Compared with the normal HR profile, the HR curve of hyperthyroid patients was shifted to a higher level (about 20 beats/min). Serum T3 level correlated best with HR at night in hyperthyroid patients (r = 0.74, p less than 0.001). Thus, hyperthyroid patients show frequent supraventricular arrhythmias that might be reversible during therapy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2929466     DOI: 10.1016/0002-9149(89)90142-2

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  19 in total

Review 1.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marin; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Eur J Prev Cardiol       Date:  2016-11-04       Impact factor: 7.804

Review 2.  European Heart Rhythm Association (EHRA)/European Association of Cardiovascular Prevention and Rehabilitation (EACPR) position paper on how to prevent atrial fibrillation endorsed by the Heart Rhythm Society (HRS) and Asia Pacific Heart Rhythm Society (APHRS).

Authors:  Bulent Gorenek; Antonio Pelliccia; Emelia J Benjamin; Giuseppe Boriani; Harry J Crijns; Richard I Fogel; Isabelle C Van Gelder; Martin Halle; Gulmira Kudaiberdieva; Deirdre A Lane; Torben Bjerregaard Larsen; Gregory Y H Lip; Maja-Lisa Løchen; Francisco Marín; Josef Niebauer; Prashanthan Sanders; Lale Tokgozoglu; Marc A Vos; David R Van Wagoner; Laurent Fauchier; Irina Savelieva; Andreas Goette; Stefan Agewall; Chern-En Chiang; Márcio Figueiredo; Martin Stiles; Timm Dickfeld; Kristen Patton; Massimo Piepoli; Ugo Corra; Pedro Manuel Marques-Vidal; Pompilio Faggiano; Jean-Paul Schmid; Ana Abreu
Journal:  Europace       Date:  2017-02-01       Impact factor: 5.214

3.  Atrial tachyarrhythmias induced by the combined effects of β1/2-adrenergic autoantibodies and thyroid hormone in the rabbit.

Authors:  Hongliang Li; Benjamin J Scherlag; David C Kem; Alexandria Benbrook; Ling Zhang; Bing Huang; Madeleine W Cunningham; Ralph Lazzara; Xichun Yu
Journal:  J Cardiovasc Transl Res       Date:  2014-06-06       Impact factor: 4.132

4.  Heart rate reduction with ivabradine prevents thyroid hormone-induced cardiac remodeling in rat.

Authors:  Bo Hyun Kim; Kyoung Im Cho; Seong Man Kim; Nari Kim; Jin Han; Jee Yeon Kim; In Ju Kim
Journal:  Heart Vessels       Date:  2012-11-11       Impact factor: 2.037

Review 5.  Cardiovascular involvement in patients with different causes of hyperthyroidism.

Authors:  Bernadette Biondi; George J Kahaly
Journal:  Nat Rev Endocrinol       Date:  2010-06-29       Impact factor: 43.330

6.  Fatty acid metabolism and thyroid hormones.

Authors:  Naomi L Sayre; James D Lechleiter
Journal:  Curr Trends Endocinol       Date:  2012-01-01

Review 7.  Arrhythmia and thyroid dysfunction.

Authors:  S Marrakchi; F Kanoun; S Idriss; I Kammoun; S Kachboura
Journal:  Herz       Date:  2014-07-04       Impact factor: 1.443

8.  Relation of endocrine and cardiac findings in acromegalics.

Authors:  G Kahaly; C Stover; J Beyer; S Mohr-Kahaly
Journal:  J Endocrinol Invest       Date:  1992-01       Impact factor: 4.256

9.  Thyroid status and diabetes modulate regional differences in potassium currents in rat ventricle.

Authors:  Y Shimoni; D Severson; W Giles
Journal:  J Physiol       Date:  1995-11-01       Impact factor: 5.182

10.  Effectiveness and safety of the tri-iodothyronine analogue Triac in children and adults with MCT8 deficiency: an international, single-arm, open-label, phase 2 trial.

Authors:  Stefan Groeneweg; Robin P Peeters; Carla Moran; Athanasia Stoupa; Françoise Auriol; Davide Tonduti; Alice Dica; Laura Paone; Klara Rozenkova; Jana Malikova; Adri van der Walt; Irenaeus F M de Coo; Anne McGowan; Greta Lyons; Femke K Aarsen; Diana Barca; Ingrid M van Beynum; Marieke M van der Knoop; Jurgen Jansen; Martien Manshande; Roelineke J Lunsing; Stan Nowak; Corstiaan A den Uil; M Carola Zillikens; Frank E Visser; Paul Vrijmoeth; Marie Claire Y de Wit; Nicole I Wolf; Angelique Zandstra; Gautam Ambegaonkar; Yogen Singh; Yolanda B de Rijke; Marco Medici; Enrico S Bertini; Sylvia Depoorter; Jan Lebl; Marco Cappa; Linda De Meirleir; Heiko Krude; Dana Craiu; Federica Zibordi; Isabelle Oliver Petit; Michel Polak; Krishna Chatterjee; Theo J Visser; W Edward Visser
Journal:  Lancet Diabetes Endocrinol       Date:  2019-07-31       Impact factor: 32.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.